ZYME Q2 2025 Earnings — Zymeworks Inc. Revenue & Financial Results | Market Cap Arena

ZYMEZymeworks Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$49M+153.2% YoY

Gross Profit

$49M100.0% margin

Operating Income

-$674,000-1.4% margin

Net Income

$2M4.8% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+79.7%

Cash Flow

Operating Cash Flow

$12M

Free Cash Flow

$11M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$408M

Total Liabilities

$74M

Stockholders' Equity

$335M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$49M	$19M	+153.2%
Gross Profit	$49M	$19M	+153.2%
Operating Income	-$674,000	-$43M	+98.4%
Net Income	$2M	-$38M	+106.1%

Revenue Segments

Milestone Revenue

$20M43%

Deferred Revenue

$18M39%

Option Exercise Fee

$8M16%

Royalty

$550,0001%

Research Support Payments And Other Service

$475,0001%